Glaucoma News and Research

Latest Glaucoma News and Research

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

Ivantis announced today at the World Glaucoma Congress in Paris that it has received $17 MM in funding from New Enterprise Associates (NEA) and Delphi Ventures.

27 Jun 2011

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

A side effect of many commonly used drugs appears to increase the risks of both cognitive impairment and death in older people, according to new research led by the University of East Anglia.

24 Jun 2011

New VEP technique fast and effective for detecting glaucoma damage

A recent paper published in the Journal of Glaucoma shows a new visual evoked potential (VEP) technique to be a fast, objective method to screen for functional damage in glaucomatous eyes.

22 Jun 2011

Functional vision restored after 55 years

After being hit in the eye by a stone, a detached retina left a man blind in his right eye. Despite surgery to remove a cataract when the man was 23, which temporarily restored light perception, the patient was completely blind in that eye.

17 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.

15 Jun 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

Schepens, Mass. Eye and Ear to create world's largest ophthalmology research center

The Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute announced today that they are combining forces to create the world's largest and most robust basic and clinical ophthalmology research enterprise with full spectrum bench-to-bedside research that will translate more quickly into better treatment for blinding diseases and ultimately cures.

10 Jun 2011

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

Somaxon Pharmaceuticals, Inc. and Paladin Labs Inc. today announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and Africa.

8 Jun 2011

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

The new Montefiore Laser and Eye Center recently opened its doors to provide comprehensive care to Westchester patients at the Montefiore Medical Specialists of Westchester in Scarsdale, New York. Seven board-certified ophthalmologists from the Department of Ophthalmology and Visual Sciences at Montefiore Medical Center provide patients with specialty emphasis in pediatric ophthalmology, oculoplastic surgery, glaucoma, cornea and laser refractive surgery.

8 Jun 2011

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc.

6 Jun 2011

Research: Gene mutation causes eye disease glaucoma

It is a mutation in a gene that causes the eye disease glaucoma, according to collaborative research conducted by Swedish, Tunisian, and American researchers. The findings were recently published in the journal Nature Genetics.

31 May 2011

Wills Eye Institute and Thomas Jefferson University create new vision research center

A new vision research center based in Philadelphia will foster regional, national and global collaborations among a diverse group of exceptional clinicians and researchers working to better diagnose, treat and prevent visual diseases.

21 May 2011

The Incubation Factory, UMDNJ and NJIT partner to commercialize personal tonometer for glaucoma

NJIT and UMDNJ have executed a license agreement with The Incubation Factory, St. Louis, MO, covering their personal tonometer technology on which a patent is pending. The tonometer was developed by a research team led by NJIT Professor Gordon Thomas, PhD, and Robert Fechtner, MD, director of the glaucoma division at UMDNJ.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

Fifty patients to receive complimentary cataract surgery from Kremer Eye Center

A team from Kremer Eye Center is traveling to Belize City, Belize to provide essential eye care June 18-25, 2011. Fifty patients will receive complimentary cataract surgery.

17 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

Kowa presents three K-115 study results against glaucoma at ARVO 2011

Kowa Company Ltd, today announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension.

10 May 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that data from a clinical study of PRM-151 will be presented at the 2011 American Thoracic Society International Conference, being held May 13-18, 2011 in Denver, CO.

5 May 2011

Glaucoma News and Research

Latest Glaucoma News and Research

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

New VEP technique fast and effective for detecting glaucoma damage

Functional vision restored after 55 years

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Schepens, Mass. Eye and Ear to create world's largest ophthalmology research center

Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa

New Westchester Montefiore Laser and Eye Center to offer ophthalmology services

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Research: Gene mutation causes eye disease glaucoma

Wills Eye Institute and Thomas Jefferson University create new vision research center

The Incubation Factory, UMDNJ and NJIT partner to commercialize personal tonometer for glaucoma

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Fifty patients to receive complimentary cataract surgery from Kremer Eye Center

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

Kowa presents three K-115 study results against glaucoma at ARVO 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Glaucoma News and Research

Latest Glaucoma News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in